News & Updates

Individuals with metabolic syndrome who are hospitalized for COVID-19 may have a greater risk for more severe COVID-19 disease, including an elevated risk of in-hospital mortality, acute respiratory distress syndrome (ARDS), and intensive care unit (ICU) admission, a recent prospective study showed.

The risk for hip fracture slightly increases following osteoporosis drug holidays after long-term therapy with risedronate compared with alendronate, a study has found, adding that future research must examine how best to lessen such risk.

The nonsteroidal topical aryl hydrocarbon receptor (AHR)-modulating agent tapinarof 1% trumped a vehicle control cream in reducing the severity and manifestations of plaque psoriasis, according to the phase III PSOARING 1 and 2 trials.

Adding aspirin to usual care did not lead to a reduced mortality rate in patients hospitalized with COVID-19, according to a study by the RECOVERY* Collaborative Group.

Epstein-Barr virus (EBV) may be the first trigger for the development of multiple sclerosis (MS) in most cases, says an expert.

Oral sitafloxacin was just as effective and safe as levofloxacin for the treatment of complicated and uncomplicated urinary tract infections (UTIs) in adults, according to a phase III study from China.

There is no apparent increased risk of deep vein thrombosis (DVT) following receipt of the COVID-19 vaccine, according to a study presented at ASH 2021.

In the treatment of patients with COVID-19, administering remdesivir within 5 days of symptom onset appears to reduce the risk of progression to severe disease, as shown in a study.

In the phase II proof-of-concept CATALYST trial comparing the GM-CSF* inhibitor namilumab and the TNF** inhibitor infliximab against usual care (UC), namilumab, but not infliximab, demonstrated signals for reducing inflammation in hospitalized patients with COVID-19 pneumonia.